Relay Therapeutics stock
RLAYNASDAQRelay Therapeutics, Inc., HealthcareISIN US75943R1023
46Score 46 out of 100, Weak
Price and trend
89 / 100
Price history
+193% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 17% above it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 50).
The price is 13% below its 52-week high. Largest decline in 6 years: 97% (January 2021 to April 2025).
Chart figures for advanced users
- SMA 50$18.39
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.49
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)50
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.17
- The lowest closing price of the last twelve months.
- Resistance$20.75
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Relay Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $3.99B, is number 83 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $15.36M (up 53.4% year on year) and a loss of $276.48M.
- For fiscal 2026, analysts expect on average revenue of $11.16M (down 27.3%) and adjusted earnings per share of −$1.60.
Show more
- MEQIRI Score 46 out of 100 (Weak): rank 452 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $848.64M, financial debt $27.03M.Stability 70
Weaknesses
- DilutionShare count up 91% since 2020.Capital allocation 18
- Revenue shrinkingRevenue down 28.6% a year since 2020.Growth 32
- Loss-makingLoss of $293.63M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 45 to 46.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 53.4% on the prior year. Revenue turned from negative at the start of the period to positive ($15.36M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 77%, operating −1972%, net −1801%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 4 Nov 2026EPS reported −$0.37 (expected −$0.40)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.600.0%
- Revenue
- $11.16M0.0%
- Earnings per share
- −$1.610.0%
- Revenue
- $19.54M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $125.98M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Rahmer PeterSale
28 Oct 2026, See remarks
- Shares
- 753
- Price
- $18.62
- Value
- $14,021
- Bergstrom Donald ASale
28 Oct 2026, President, R&D
- Shares
- 2,252
- Price
- $18.62
- Value
- $41,932
- Catinazzo ThomasSale
28 Oct 2026, Chief Financial Officer
- Shares
- 1,469
- Price
- $18.62
- Value
- $27,353
Show 19 more
- Patel SanjivSale
7 Oct 2026, President and CEO
- Shares
- 48,199
- Price
- $18.10
- Value
- $872,402
- Catinazzo ThomasSale
6 Oct 2026, Chief Financial Officer
- Shares
- 17,717
- Price
- $18.59
- Value
- $329,322
- Bergstrom Donald ASale
8 Sept 2026, President, R&D
- Shares
- 8,530
- Price
- $18.97
- Value
- $161,814
- Catinazzo ThomasSale
8 Sept 2026, Chief Financial Officer
- Shares
- 17,717
- Price
- $18.94
- Value
- $335,560
- Patel SanjivSale
8 Sept 2026, President and CEO
- Shares
- 48,199
- Price
- $18.94
- Value
- $912,889
- Rahmer PeterSale
26 Aug 2026, See remarks
- Shares
- 4,508
- Price
- $20.03
- Value
- $90,295
- SVF Pauling (Cayman) LtdSale
25 Aug 2026, Major holder
- Shares
- 6,000,000
- Price
- $19.40
- Value
- $116.4M
- Patel SanjivSale
17 Aug 2026, President and CEO
- Shares
- 48,199
- Price
- $20.33
- Value
- $979,886
- Catinazzo ThomasSale
14 Aug 2026, Chief Financial Officer
- Shares
- 17,717
- Price
- $19.74
- Value
- $349,734
- Catinazzo ThomasSale
28 Jul 2026, Chief Financial Officer
- Shares
- 1,459
- Price
- $18.61
- Value
- $27,152
- Rahmer PeterSale
28 Jul 2026, See remarks
- Shares
- 748
- Price
- $18.61
- Value
- $13,920
- Bergstrom Donald ASale
28 Jul 2026, President, R&D
- Shares
- 2,237
- Price
- $18.61
- Value
- $41,631
- Patel SanjivSale
7 Jul 2026, President and CEO
- Shares
- 48,199
- Price
- $19.58
- Value
- $943,736
- Bergstrom Donald ASale
6 Jul 2026, President, R&D
- Shares
- 8,660
- Price
- $18.71
- Value
- $162,029
- Catinazzo ThomasSale
6 Jul 2026, Chief Financial Officer
- Shares
- 17,717
- Price
- $18.69
- Value
- $331,131
- Rahmer PeterSale
30 Jun 2026, See remarks
- Shares
- 50,000
- Price
- $19.09
- Value
- $954,500
- Catinazzo ThomasSale
22 Jun 2026, Chief Financial Officer
- Shares
- 69,277
- Price
- $16.98
- Value
- $1.18M
- Bergstrom Donald ASale
22 Jun 2026, President, R&D
- Shares
- 93,456
- Price
- $16.94
- Value
- $1.58M
- Catinazzo ThomasSale
14 May 2026, Chief Financial Officer
- Shares
- 17,717
- Price
- $12.86
- Value
- $227,841
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Relay Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 46
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Ionis PharmaceuticalsIONS $4.72B32
- Definium TherapeuticsDFTX $4.63B41
- CRISPR TherapeuticsCRSP $4.44B37
- CamurusCAMX.ST $4.42B74
- Tango TherapeuticsTNGX $4.34B45
- Xenon PharmaceuticalsXENE $4.14B37
- Amylyx PharmaceuticalsAMLX $4.09B43
- AbCellera BiologicsABCL $3.9B38
ETFs that hold Relay Therapeutics
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 0.88% | 0.89% | €11.61M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.27% | 0.40% | €1.49B |
| iShares Ageing Population UCITS ETF2B77 | 0.26% | 0.40% | €807M |
Show 5 more
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.24% | 0.35% | €1.21B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.13% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.12% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.12% | 0.30% | €4.22B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.06% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.